John O. Barron
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
John O. Barron has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
Eugene H. Blackstone
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio; Department of Quantitative Health Sciences, Cleveland Clinic, Cleveland, Ohio
4 shared publicationsSudish C. Murthy
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio
4 shared publicationsAndrew J. Toth
Department of Quantitative Health Sciences, Research Institute
3 shared publicationsSadia Tasnim
Department of Thoracic and Cardiovascular Surgery, Heart, Vascular, and Thoracic Institute
3 shared publications- Siva Raja
Department of Thoracic and Cardiovascular Surgery, Cleveland Clinic, Cleveland, Ohio
3 shared publications Daniel P. Raymond
2 shared publications
Latest Publications
- Open Access
- 10 October 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 121 (5) , 1211-1220
Lung Transplant Outcomes in the Veterans Health Administration
- 10 October 2025
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 121 (5) , 1211-1220
Open AccessLung Transplant Outcomes in the Veterans Health Administration
- 18 June 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 170 (6) , 1821-1830.e4
Heller myotomy for esophageal achalasia: Outcomes in 1010 patients with longitudinal follow-up
- 18 June 2025
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 170 (6) , 1821-1830.e4
Heller myotomy for esophageal achalasia: Outcomes in 1010 patients with longitudinal follow-up
- 4 March 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (2) , e14738
Ten‐year follow‐up of cavoportal hemitransposition in pediatric liver transplantation for complete portomesenteric venous thrombosis: A case report and literature review
Background: Portal vein thrombosis is a potentially devastating complication following pediatric liver transplantation. In rare instances of complete portomesenteric thrombosis, cavoportal hemitransposition may provide graft inflow. Here we describe long‐term results following a case of pediatric cavoportal hemitransposition during liver transplantation and review the current pediatric literature.Methods: A 9‐month‐old female with a history of biliary atresia and failed Kasai portoenterostomy underwent living donor liver transplantation, which was complicated by portomesenteric venous thrombosis. The patient underwent retransplantation with cavoportal hemitransposition on postoperative day 12.Outcome: The patient recovered without further complication, and 10 years later, she continues to do well, with normal graft function and no clinical sequelae of portal hypertension. CT scan with 3‐D vascular reconstruction demonstrated recanalization of the splanchnic system, with systemic drainage to the inferior vena cava via an inferior mesenteric vein shunt. The cavoportal anastomosis remains patent with hepatopetal flow. Of the 12 previously reported cases of pediatric cavoportal hemitransposition as portal inflow in liver transplantation, this is the longest‐known follow‐up with a viable allograft. Notably, sequelae of portal hypertension were also rare in the 12 previously reported cases, with no cases of long‐term renal dysfunction, lower extremity edema, or ascites.Conclusions: Long‐term survival beyond 10 years with normal graft function is feasible following pediatric cavoportal hemitransposition. Complications related to portal hypertension were generally short‐lived, likely due to the development of robust collateral circulation. Additional reports of long‐term outcomes are necessary to facilitate informed decision making when considering pediatric cavoportal hemitransposition for liver graft inflow.
- 4 March 2024
- Published by Wiley in Pediatric Transplantation
- Vol. 28 (2) , e14738
Ten‐year follow‐up of cavoportal hemitransposition in pediatric liver transplantation for complete portomesenteric venous thrombosis: A case report and literature review
Background: Portal vein thrombosis is a potentially devastating complication following pediatric liver transplantation. In rare instances of complete portomesenteric thrombosis, cavoportal hemitransposition may provide graft inflow. Here we describe long‐term results following a case of pediatric cavoportal hemitransposition during liver transplantation and review the current pediatric literature.Methods: A 9‐month‐old female with a history of biliary atresia and failed Kasai portoenterostomy underwent living donor liver transplantation, which was complicated by portomesenteric venous thrombosis. The patient underwent retransplantation with cavoportal hemitransposition on postoperative day 12.Outcome: The patient recovered without further complication, and 10 years later, she continues to do well, with normal graft function and no clinical sequelae of portal hypertension. CT scan with 3‐D vascular reconstruction demonstrated recanalization of the splanchnic system, with systemic drainage to the inferior vena cava via an inferior mesenteric vein shunt. The cavoportal anastomosis remains patent with hepatopetal flow. Of the 12 previously reported cases of pediatric cavoportal hemitransposition as portal inflow in liver transplantation, this is the longest‐known follow‐up with a viable allograft. Notably, sequelae of portal hypertension were also rare in the 12 previously reported cases, with no cases of long‐term renal dysfunction, lower extremity edema, or ascites.Conclusions: Long‐term survival beyond 10 years with normal graft function is feasible following pediatric cavoportal hemitransposition. Complications related to portal hypertension were generally short‐lived, likely due to the development of robust collateral circulation. Additional reports of long‐term outcomes are necessary to facilitate informed decision making when considering pediatric cavoportal hemitransposition for liver graft inflow.
- 28 January 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 118 (2) , 402-411
Thoracoabdominal Esophagectomy: Then and Now
- 28 January 2024
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 118 (2) , 402-411
Thoracoabdominal Esophagectomy: Then and Now
- Open Access
- 15 January 2024
- Published by Korean Society for Thoracic and Cardiovascular Surgery in Journal of Chest Surgery
- Vol. 57 (2) , 213-216
Novel Repair of Clamshell Thoracotomy Sternal Dehiscence after Lung Transplant: A Case Report
John O. Barron, M.D., Nethra Jain, M.B.B.S., Mujtaba Mubashir, M.D., Haytham Elgharably, M.D., Daniel P. Raymond, M.D., Dean P. Schraufnagel, M.D.. J Chest Surg 2024;57:213-6. https://doi.org/10.5090/jcs.23.099
- 15 January 2024
- Published by Korean Society for Thoracic and Cardiovascular Surgery in Journal of Chest Surgery
- Vol. 57 (2) , 213-216
Open AccessNovel Repair of Clamshell Thoracotomy Sternal Dehiscence after Lung Transplant: A Case Report
John O. Barron, M.D., Nethra Jain, M.B.B.S., Mujtaba Mubashir, M.D., Haytham Elgharably, M.D., Daniel P. Raymond, M.D., Dean P. Schraufnagel, M.D.. J Chest Surg 2024;57:213-6. https://doi.org/10.5090/jcs.23.099
- 20 July 2023
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 117 (3) , 594-601
The Value of Fundoplication in the Treatment of Type I Achalasia
- 20 July 2023
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 117 (3) , 594-601
The Value of Fundoplication in the Treatment of Type I Achalasia
- 1 October 2021
- Published by Elsevier in Journal of Surgical Research
- Vol. 266, 96-103
Travel Time to a High Volume Center Negatively Impacts Timing of Care in Rectal Cancer
- 1 October 2021
- Published by Elsevier in Journal of Surgical Research
- Vol. 266, 96-103
Travel Time to a High Volume Center Negatively Impacts Timing of Care in Rectal Cancer
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e18003
Validity of clinical information for a novel cancer care quality program.
E18003 Background: Through Anthem’s Cancer Care Quality Program (CCQP), oncologists can submit requests and accompanying clinical rationale for cancer treatments. Qualifying treatments within evidence-based pathways are eligible for enhanced reimbursement. The accuracy of clinical information within the CCQP is vital to the program’s overall effectiveness. This study evaluated the validity of the clinical information submitted to the CCQP compared with medical records of lung cancer patients obtained from treating providers. Methods: Data elements obtained relevant to this study include cancer type, stage, histology, and biomarkers (ie, ALK and EGFR mutation status). A sample of 200 lung cancer patients with CCQP requests for treatment within the HealthCore Integrated Research Environment (HIRE) – Oncology data were identified for medical record collection and review by a blinded board certified oncology pharmacist. Statistical measures of validity (agreement, positive & negative predictive value (PPV & NPV), sensitivity, and specificity) were used to compare clinical information between data sources. Results: Approximately 1300 patients with lung cancer were identified in the first year of the program (Jul 2014 – Jun 2015). Of the 200 records reviewed, 197 were confirmed to be lung cancer (PPV of 0.99) and 87% were identified as non-small cell lung cancer (NSCLC). All performance measures were ≥ 0.85, with the exception of the PPV for ALK status. Conclusions: Overall, the high agreement between the data entered for the CCQP and medical records support the validity of the clinical information for purposes of effective program implementation, administration, and research.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , e18003
Validity of clinical information for a novel cancer care quality program.
E18003 Background: Through Anthem’s Cancer Care Quality Program (CCQP), oncologists can submit requests and accompanying clinical rationale for cancer treatments. Qualifying treatments within evidence-based pathways are eligible for enhanced reimbursement. The accuracy of clinical information within the CCQP is vital to the program’s overall effectiveness. This study evaluated the validity of the clinical information submitted to the CCQP compared with medical records of lung cancer patients obtained from treating providers. Methods: Data elements obtained relevant to this study include cancer type, stage, histology, and biomarkers (ie, ALK and EGFR mutation status). A sample of 200 lung cancer patients with CCQP requests for treatment within the HealthCore Integrated Research Environment (HIRE) – Oncology data were identified for medical record collection and review by a blinded board certified oncology pharmacist. Statistical measures of validity (agreement, positive & negative predictive value (PPV & NPV), sensitivity, and specificity) were used to compare clinical information between data sources. Results: Approximately 1300 patients with lung cancer were identified in the first year of the program (Jul 2014 – Jun 2015). Of the 200 records reviewed, 197 were confirmed to be lung cancer (PPV of 0.99) and 87% were identified as non-small cell lung cancer (NSCLC). All performance measures were ≥ 0.85, with the exception of the PPV for ALK status. Conclusions: Overall, the high agreement between the data entered for the CCQP and medical records support the validity of the clinical information for purposes of effective program implementation, administration, and research.